GITNUXREPORT 2025

Glaucoma Statistics

Glaucoma affects millions, causing irreversible blindness, emphasizing early detection importance.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

Glaucoma affects over 76 million people worldwide as of 2020

Statistic 2

It is the second leading cause of blindness globally

Statistic 3

Approximately 90% of people with glaucoma live in low- and middle-income countries

Statistic 4

The prevalence of glaucoma increases with age, affecting about 10% of people over 80 years old

Statistic 5

Open-angle glaucoma is the most common form, accounting for about 70-90% of cases

Statistic 6

Glaucoma can be asymptomatic until significant vision loss occurs, making early detection difficult

Statistic 7

The global economic burden of glaucoma is estimated at over $2.2 billion annually

Statistic 8

Women are slightly more affected by glaucoma than men, particularly in older age groups

Statistic 9

About 50% of cases of glaucoma are undiagnosed, highlighting the importance of screening

Statistic 10

The prevalence of neurodegeneration in glaucoma is comparable to that in Alzheimer’s disease

Statistic 11

Glaucoma is responsible for approximately 15% of all cases of blindness worldwide

Statistic 12

Regular comprehensive eye exams are essential for early detection of glaucoma, especially after age 40

Statistic 13

Glaucoma can lead to tunnel vision, severely restricting peripheral vision, eventually causing legal blindness if untreated

Statistic 14

The prevalence of primary angle-closure glaucoma varies by ethnicity, being more common in Asian populations

Statistic 15

The Global Initiative for Geographical and Strategic Action (GIGA) estimates that 60-70 million people globally are affected by angle-closure glaucoma

Statistic 16

Glaucoma-related blindness accounts for about 12% of all cases of blindness worldwide

Statistic 17

The rate of blindness due to glaucoma increases significantly after age 60, particularly in underserved populations

Statistic 18

African Americans are three to four times more likely to develop glaucoma compared to Caucasians, especially at a younger age

Statistic 19

Automated visual field tests are often used for glaucoma screening in large populations due to their efficiency

Statistic 20

The incidence of glaucoma varies worldwide, with higher prevalence reported in African and Asian populations, depending on the type

Statistic 21

The typical age of diagnosis for primary open-angle glaucoma is between 40 and 70 years, but it can occur earlier in high-risk groups

Statistic 22

The prevalence of blindness due to glaucoma is higher in urban than rural areas, due to better detection and healthcare access in cities

Statistic 23

Nearly 4 million people worldwide are blind due to glaucoma, with the majority in developing countries

Statistic 24

The progression of glaucoma is generally slow, often over decades, making regular monitoring critical

Statistic 25

A significant portion of glaucoma patients develop visual field defects before perceiving symptoms, underscoring the need for regular screening

Statistic 26

The Rolex Institute estimates that timely glaucoma diagnosis could prevent up to 30% of blindness cases annually if detected early

Statistic 27

Approximately 25-30% of patients with glaucoma also have other ocular diseases such as cataracts or diabetic retinopathy, complicating management

Statistic 28

Globally, over 5 million people are visually impaired due to untreated glaucoma, indicating a large gap in screening and treatment

Statistic 29

The incidence of normal-tension glaucoma is higher in Japanese and Chinese populations, accounting for about 30% of glaucomas in these groups

Statistic 30

Glaucoma causes about 8% of cases of legal blindness in the United States, representing a significant public health issue

Statistic 31

The implementation of screening programs in certain countries has doubled early diagnosis rates of glaucoma, leading to better outcomes

Statistic 32

Ongoing research is exploring neuroprotective agents to halt or slow neurodegeneration in glaucoma

Statistic 33

Advancements in imaging technologies like optical coherence tomography (OCT) have improved early detection accuracy

Statistic 34

The development of neuroprotective drugs aims to prevent retinal ganglion cell death, a hallmark of glaucoma pathophysiology

Statistic 35

The use of artificial intelligence (AI) in analyzing retinal images is promising for early glaucoma detection, with accuracy comparable to experts

Statistic 36

There is ongoing research into gene therapy approaches, aiming to modify or repair damaged optic nerves in glaucoma

Statistic 37

Patients with glaucoma often experience difficulty recognizing faces and reading at advanced stages, impacting daily life quality

Statistic 38

Elevated intraocular pressure is a major risk factor for glaucoma but not the only cause

Statistic 39

African Americans are at significantly higher risk of developing glaucoma at a younger age

Statistic 40

The risk of developing glaucoma increases with higher intraocular pressure, age, ethnicity, and family history

Statistic 41

The optic nerve damage caused by glaucoma is irreversible, making early diagnosis crucial to prevent significant vision loss

Statistic 42

Close to 50% of glaucoma patients are over the age of 60, reflecting age as a significant risk factor

Statistic 43

Family history increases the risk of developing glaucoma by up to 4-9 times, emphasizing the importance of screening for at-risk individuals

Statistic 44

People with high myopia have an increased risk of developing glaucoma, by approximately 2-3 times, especially in open-angle types

Statistic 45

The risk of glaucoma in individuals with a first-degree relative with the condition is approximately 4-9 times higher, emphasizing family screening importance

Statistic 46

Intraocular pressure (IOP) can be controlled with medications, laser treatment, or surgery

Statistic 47

The goal of glaucoma treatment is to prevent or slow down vision loss, not to restore lost vision

Statistic 48

The cost of glaucoma management in the USA exceeds $2.9 billion annually, including direct medical costs and lost productivity

Statistic 49

The use of intraocular pressure-lowering eye drops is the most common initial treatment for glaucoma

Statistic 50

Laser trabeculoplasty is a common procedure used to lower IOP in open-angle glaucoma, especially if medications fail

Statistic 51

The use of combination eye drops can enhance intraocular pressure control compared to monotherapy, especially in advanced glaucoma

Statistic 52

Visual field testing is essential in monitoring glaucoma progression over time, helping guide treatment plans

Statistic 53

In some cases, minimally invasive glaucoma surgeries (MIGS) offer safer alternatives with fewer complications than traditional surgeries

Statistic 54

Glaucoma treatment adherence remains a challenge, with studies showing up to 60% of patients do not stick to their medication regimen

Statistic 55

Studies suggest that lowering intraocular pressure can delay or prevent the onset of glaucomatous damage in predisposed individuals

Statistic 56

Intraocular pressure reduction of about 20-25% is often targeted in glaucoma management to prevent progression

Statistic 57

The early use of laser therapy can be effective in reducing IOP and delaying the need for medications in some patients

Statistic 58

Visual field loss in glaucoma patients often starts peripherally and progresses centrally

Statistic 59

In developed countries, approximately 60% of glaucoma cases are open-angle glaucoma, while angle-closure glaucoma is more prevalent in Asian populations

Statistic 60

The detection of glaucoma often involves measuring intraocular pressure, assessing optic nerve health, and evaluating visual fields

Statistic 61

The group of health conditions termed ocular hypertension involves elevated IOP without optic nerve damage, which can progress to glaucoma if untreated

Slide 1 of 61

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

Glaucoma affects over 76 million people worldwide as of 2020
It is the second leading cause of blindness globally
Approximately 90% of people with glaucoma live in low- and middle-income countries
The prevalence of glaucoma increases with age, affecting about 10% of people over 80 years old
Open-angle glaucoma is the most common form, accounting for about 70-90% of cases
Elevated intraocular pressure is a major risk factor for glaucoma but not the only cause
Glaucoma can be asymptomatic until significant vision loss occurs, making early detection difficult
Visual field loss in glaucoma patients often starts peripherally and progresses centrally
The global economic burden of glaucoma is estimated at over $2.2 billion annually
Women are slightly more affected by glaucoma than men, particularly in older age groups
African Americans are at significantly higher risk of developing glaucoma at a younger age
About 50% of cases of glaucoma are undiagnosed, highlighting the importance of screening
Intraocular pressure (IOP) can be controlled with medications, laser treatment, or surgery

Did you know that over 76 million people worldwide are affected by glaucoma, the second leading cause of blindness, yet nearly half remain undiagnosed until significant vision loss occurs?

Epidemiology and Prevalence

Glaucoma affects over 76 million people worldwide as of 2020
It is the second leading cause of blindness globally
Approximately 90% of people with glaucoma live in low- and middle-income countries
The prevalence of glaucoma increases with age, affecting about 10% of people over 80 years old
Open-angle glaucoma is the most common form, accounting for about 70-90% of cases
Glaucoma can be asymptomatic until significant vision loss occurs, making early detection difficult
The global economic burden of glaucoma is estimated at over $2.2 billion annually
Women are slightly more affected by glaucoma than men, particularly in older age groups
About 50% of cases of glaucoma are undiagnosed, highlighting the importance of screening
The prevalence of neurodegeneration in glaucoma is comparable to that in Alzheimer’s disease
Glaucoma is responsible for approximately 15% of all cases of blindness worldwide
Regular comprehensive eye exams are essential for early detection of glaucoma, especially after age 40
Glaucoma can lead to tunnel vision, severely restricting peripheral vision, eventually causing legal blindness if untreated
The prevalence of primary angle-closure glaucoma varies by ethnicity, being more common in Asian populations
The Global Initiative for Geographical and Strategic Action (GIGA) estimates that 60-70 million people globally are affected by angle-closure glaucoma
Glaucoma-related blindness accounts for about 12% of all cases of blindness worldwide
The rate of blindness due to glaucoma increases significantly after age 60, particularly in underserved populations
African Americans are three to four times more likely to develop glaucoma compared to Caucasians, especially at a younger age
Automated visual field tests are often used for glaucoma screening in large populations due to their efficiency
The incidence of glaucoma varies worldwide, with higher prevalence reported in African and Asian populations, depending on the type
The typical age of diagnosis for primary open-angle glaucoma is between 40 and 70 years, but it can occur earlier in high-risk groups
The prevalence of blindness due to glaucoma is higher in urban than rural areas, due to better detection and healthcare access in cities
Nearly 4 million people worldwide are blind due to glaucoma, with the majority in developing countries
The progression of glaucoma is generally slow, often over decades, making regular monitoring critical
A significant portion of glaucoma patients develop visual field defects before perceiving symptoms, underscoring the need for regular screening
The Rolex Institute estimates that timely glaucoma diagnosis could prevent up to 30% of blindness cases annually if detected early
Approximately 25-30% of patients with glaucoma also have other ocular diseases such as cataracts or diabetic retinopathy, complicating management
Globally, over 5 million people are visually impaired due to untreated glaucoma, indicating a large gap in screening and treatment
The incidence of normal-tension glaucoma is higher in Japanese and Chinese populations, accounting for about 30% of glaucomas in these groups
Glaucoma causes about 8% of cases of legal blindness in the United States, representing a significant public health issue
The implementation of screening programs in certain countries has doubled early diagnosis rates of glaucoma, leading to better outcomes

Epidemiology and Prevalence Interpretation

With over 76 million affected worldwide and half of cases undiagnosed, glaucoma's silent progression and its status as a leading cause of preventable blindness underscore the urgent need for widespread screening, especially given its disproportionate impact on vulnerable populations and the aging global demographic.

Research and Future Developments

Ongoing research is exploring neuroprotective agents to halt or slow neurodegeneration in glaucoma
Advancements in imaging technologies like optical coherence tomography (OCT) have improved early detection accuracy
The development of neuroprotective drugs aims to prevent retinal ganglion cell death, a hallmark of glaucoma pathophysiology
The use of artificial intelligence (AI) in analyzing retinal images is promising for early glaucoma detection, with accuracy comparable to experts
There is ongoing research into gene therapy approaches, aiming to modify or repair damaged optic nerves in glaucoma
Patients with glaucoma often experience difficulty recognizing faces and reading at advanced stages, impacting daily life quality

Research and Future Developments Interpretation

While cutting-edge imaging, AI, and gene therapy hold promise for revolutionizing glaucoma care, early detection remains key to preventing the disease’s stealthy progression from jeopardizing patients' ability to recognize faces and read—reminding us that even in the age of technology, vigilance is our best sight.

Risk Factors and Demographics

Elevated intraocular pressure is a major risk factor for glaucoma but not the only cause
African Americans are at significantly higher risk of developing glaucoma at a younger age
The risk of developing glaucoma increases with higher intraocular pressure, age, ethnicity, and family history
The optic nerve damage caused by glaucoma is irreversible, making early diagnosis crucial to prevent significant vision loss
Close to 50% of glaucoma patients are over the age of 60, reflecting age as a significant risk factor
Family history increases the risk of developing glaucoma by up to 4-9 times, emphasizing the importance of screening for at-risk individuals
People with high myopia have an increased risk of developing glaucoma, by approximately 2-3 times, especially in open-angle types
The risk of glaucoma in individuals with a first-degree relative with the condition is approximately 4-9 times higher, emphasizing family screening importance

Risk Factors and Demographics Interpretation

While elevated intraocular pressure and age remain key risk factors for glaucoma, the disease’s silent, irreversible optic nerve damage—especially prevalent among African Americans, those with family histories, or high myopia—underscores the urgent need for targeted early screening in at-risk populations to prevent preventable blindness.

Treatment and Management Options

Intraocular pressure (IOP) can be controlled with medications, laser treatment, or surgery
The goal of glaucoma treatment is to prevent or slow down vision loss, not to restore lost vision
The cost of glaucoma management in the USA exceeds $2.9 billion annually, including direct medical costs and lost productivity
The use of intraocular pressure-lowering eye drops is the most common initial treatment for glaucoma
Laser trabeculoplasty is a common procedure used to lower IOP in open-angle glaucoma, especially if medications fail
The use of combination eye drops can enhance intraocular pressure control compared to monotherapy, especially in advanced glaucoma
Visual field testing is essential in monitoring glaucoma progression over time, helping guide treatment plans
In some cases, minimally invasive glaucoma surgeries (MIGS) offer safer alternatives with fewer complications than traditional surgeries
Glaucoma treatment adherence remains a challenge, with studies showing up to 60% of patients do not stick to their medication regimen
Studies suggest that lowering intraocular pressure can delay or prevent the onset of glaucomatous damage in predisposed individuals
Intraocular pressure reduction of about 20-25% is often targeted in glaucoma management to prevent progression
The early use of laser therapy can be effective in reducing IOP and delaying the need for medications in some patients

Treatment and Management Options Interpretation

While glaucoma treatments—from eye drops to laser surgeries—offer promising avenues to slow vision loss and contain a $2.9 billion annual cost, the true challenge remains ensuring patient adherence so that the focus stays on protecting sight rather than inadvertently turning prevention into an expensive gamble.

Types and Forms of Glaucoma

Visual field loss in glaucoma patients often starts peripherally and progresses centrally
In developed countries, approximately 60% of glaucoma cases are open-angle glaucoma, while angle-closure glaucoma is more prevalent in Asian populations
The detection of glaucoma often involves measuring intraocular pressure, assessing optic nerve health, and evaluating visual fields
The group of health conditions termed ocular hypertension involves elevated IOP without optic nerve damage, which can progress to glaucoma if untreated

Types and Forms of Glaucoma Interpretation

Glaucoma's insidious progression from peripheral to central vision loss, coupled with its varied prevalence and the importance of early detection through pressure and nerve assessments, underscores that ocular hypertension may be a silent threat—if left unchecked, it can silently march toward irreversible blindness.